Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601969 | 0.84 | NAMPT (0.53) | NAMPTLMNAFAAHTSHRMAPK1 | |
| SCHEMBL3562002 | 0.74 | PTPN1 (0.58) | NAMPTLMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL13074367 | 0.70 | MEN1 (0.59) | NAMPTLMNAFAAHTSHRMAPK1 | |
| SCHEMBL13037186 | 0.70 | MEN1 (0.59) | NAMPTLMNAFAAHTSHRMAPK1 | |
| SCHEMBL13037189 | 0.67 | NOS2 (0.57) | NAMPTNOS2 | |
| SCHEMBL29407510 | 0.67 | TSHR (0.65) | LMNAFAAHTSHRMAPK1NPC1 | |
| SCHEMBL3378134 | 0.67 | TSHR (0.65) | LMNAFAAHTSHRMAPK1NPC1 | |
| SCHEMBL107447 | 0.66 | PPARD (0.46) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4649730 | 0.66 | NAMPT (0.42) | NAMPTTSHRMAPK1ALDH1A1HPGD | |
| SCHEMBL927331 | 0.66 | ALDH1A1 (0.50) | NAMPTLMNATSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225890-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND PARKINSON'S DISEASE | PROTAMED, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | PROTAMED, INC. | 2011-07-14 | — | — | US | disclosed |
| US-7919530-B2 | Compounds, compositions, and methods for the treatment of synucleinopathies | PROTEOTECH, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100179223-A1 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies | PROTAMED, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | SNOW ALAN D | 2009-08-06 | — | — | US | disclosed |
| US-7514583-B2 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTEOTECH, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179223-A1 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies | SNCA, PARK7, COMT | NAMPT 2815/4885LMNA 832/4885FAAH 968/4885 |
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | NAMPT 2451/4885LMNA 1220/4885FAAH 1466/4885 |
| US-20120225890-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND PARKINSON'S DISEASE | IAPP, SNCA, APP | NAMPT 1756/4885LMNA 1113/4885FAAH 1619/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | NAMPT 2073/4885LMNA 2039/4885FAAH 444/4885 |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | IAPP, SNCA, APP | NAMPT 1756/4885LMNA 1113/4885FAAH 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.